Gynecologic Cancers: Molecular Updates 2018

Eman Abdulfatah; Quratulain Ahmed; Baraa Alosh; Sudeshna Bandyopadhyay; Martin H Bluth; Rouba Ali-Fehmi

doi:10.1016/j.cll.2018.02.007

Gynecologic Cancers: Molecular Updates 2018

Clin Lab Med. 2018 Jun;38(2):421-438. doi: 10.1016/j.cll.2018.02.007.

Authors

Eman Abdulfatah¹, Quratulain Ahmed², Baraa Alosh¹, Sudeshna Bandyopadhyay³, Martin H Bluth⁴, Rouba Ali-Fehmi¹

Affiliations

¹ Department of Pathology, Detroit Medical Center Harper University Hospital, Wayne State University, 3990 John R Detroit, MI 48201, USA.
² Michigan Diagnostic pathologists, Providence Hospital, 16001 W Nine Mile Road, Southfield, MI 48075, USA.
³ Department of Pathology, Detroit Medical Center Harper University Hospital, Wayne State University, 3990 John R Detroit, MI 48201, USA. Electronic address: SBandyop@dmc.org.
⁴ Department of Pathology, Wayne State University, School of Medicine, 540 East Canfield Street, Detroit, MI 48201, USA; Pathology Laboratories, Michigan Surgical Hospital, 21230 Dequindre Road, Warren, MI 48091, USA.

PMID: 29776639
DOI: 10.1016/j.cll.2018.02.007

Abstract

Ovarian carcinoma continues to be a concern for woman and maintains significant morbidity and mortality. Emerging molecular markers are providing additional opportunities for effective diagnosis and prognosis of disease. An integrated clinicopathologic and molecular classification of gynecologic malignancies has the potential to refine the clinical risk prediction of patients with cancer and to provide more tailored treatment recommendations.

Keywords: Cell free nucleic acid; Endometrial carcinoma; Molecular pathogenesis; Ovarian carcinoma; Uterine carcinoma.

Publication types

Review

MeSH terms

Female
Genital Neoplasms, Female* / diagnosis
Genital Neoplasms, Female* / genetics
Genital Neoplasms, Female* / pathology
Humans
Pathology, Molecular*